It is all about perception, and here are strong names to pick up on market weakness.
bluebird bio, Inc. (NASDAQ: BLUE) and Regeneron Pharmaceuticals, Inc.
An updated strategy for the high-flying REGN.
Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMD, ARII, GLW, NEP, REGN, UHAL Downgrades: ASTE, GEC, SINO, SXT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Regeneron Pharmaceuticals, Inc. has taken over the #154 spot from Kimberly-Clark Corp.
Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.
Jim Cramer takes a look at Kraft Heinz, VF Corp, Cimarex Energy, STORE Capital, Wheaton Precious Metals, Bluebird Bio, First Commonwealth Financial Corp.
Jim Cramer says many stocks already reflect the worst-case scenarios, and that means he sees a lot of upside potential.
Recent action tells us REGN's momentum is super strong.
Wednesday’s action tells us REGN’s momentum is super strong.
The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Collaboration will also generate preclinical data to inform Regeneron's development of human medicines
Jim Cramer talks about the stocks and sectors behind the resurgence fueling the Nasdaq's gains.
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
We have more evidence to support the bull case.
Cramer weighs in on Box, American Outdoor Brands, Lululemon Athletica, Henry Schein, Regeneron Pharmeceuticals, Opko Health and more.
Jim Cramer says these tariffs aren't that big, but this selloff is entirely rational.
TARRYTOWN, New York, May 31, 2018 /PRNewswire/ -- Regeneron working with World Health Organization, U.
Stock still needs a period of base building to support advance.
Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.
The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
